About a year after first becoming available in Europe, the ScanWatch from French medtech device maker Withings has received an FDA clearance, paving the way for a U.S. debut slated for early November.
The Mayo Clinic has tapped testing provider Personalis to offer genomic sequencing to participating cancer patients to not only help guide their treatments but also gather data for oncology research and the development of new diagnostics and therapies.
Intellia Therapeutics was the first to prove gene editing can work in a human and now the famed CRISPR/Cas9 biotech is beefing up its ocular disease pipeline with a 10% equity stake in SparingVision.
For many who may only see the inside of the powerful machines once or twice in their lifetime, getting an MRI can be a scary prospect—especially for children. Philips’ solution for making a scan less scary? Turn it into a game.
After half a decade of working together to develop software to support genomic research, Intel and the Broad Institute of MIT and Harvard are taking their relationship to the next level.
FDA warns against using over-the-counter lip and facial fillers with unauthorized needle-free devices
The FDA’s crackdown on online sales of unauthorized medical devices and substances rages on. The latest to be placed on the chopping block are dermal fillers sold over the counter and the at-home, needle-free devices used to inject them—none of which have been cleared by the FDA.
Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., is to retire at the end of the year, ending a nine-year stint at the top of the rejuvenated R&D unit and creating more turnover at the top of the Big Pharma.
Veracyte kicks off limited release of its nasal swab lung cancer test as it gears up for full commercial launch
Veracyte announced it has begun rolling out its long-awaited nasal swab test for lung cancer to a limited number of clinical sites, as it continues to build up data to back its full future commercial launch.
The status of Schrödinger’s cat may be up in the air, but Schrödinger’s computational drug discovery platform is certainly still alive and kicking.
Brain atlas unveils dozens of cell types that control movement and could inspire targets in neurological disease
When the National Institutes of Health launched the BRAIN Initiative in 2013, its ambitious goal was to bring together federal agencies, research organizations, academics and companies to improve the world’s understanding of the human neurological system. Now a team of participants led by the University of California, Berkeley, has made a major contribution to that effort.